Axial spondyloarthritis

17 trials 6 recruiting MedDRA PT
17 Registered trials
6 Recruiting
11 Unique sponsors
12 Unique IMPs
11 Commercial trials
Drug classes (ATC)
— ATC code not specified 9
L Oncology (ATC L) 7
A Gastroenterology (ATC A) 1
M Musculoskeletal (ATC M) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 5 substances
Monoclonal antibody (humanized) 3 substances
JAK inhibitor 2 substances
EGFR inhibitor 1 substance
Monoclonal antibody (chimeric) 1 substance
Phase III: 3 Phase II: 3 Phase IV: 5 Phase I: 1 Phase I (Other): 2 Other: 3

Filter these 17 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 17 trials

Phase III

3 trials
  • Alfasigma S.p.A. Commercial
    FILGOTINIB
    2022-501354-10-01 15 countries 2023 n=487
    Recruiting
  • UCB Biopharma Commercial
    BIMEKIZUMAB
    2023-506527-28-00 7 countries 2020 n=568
    Ended
  • AbbVie Deutschland GmbH & Co. KG Academic
    ABT-494
    2022-501018-78-00 9 countries 2020 n=272
    Ended

Phase II

3 trials
  • Spyre Therapeutics Inc. Commercial
    SPY072
    2025-521791-63-00 4 countries 2025 n=236
    Ended
  • Assistance Publique Hopitaux De Paris Academic
    ALLOGENEIC FAECAL MICROBIOTA, POOLED; ASCORBIC ACID, SODIUM ASCORBATE, POTASSIUM CHLORIDE, SODIUM CHLORIDE, SODIUM SULFATE ANHYDROUS, MACROGOL 3350
    2023-504852-89-00 1 country 2025 n=25 Orphan
    Recruiting
  • St. Elisabeth Gruppe GmbH Katholische Kliniken Rhein-Ruhr Academic
    RISANKIZUMAB
    2023-507718-28-00 1 country 2024 n=20
    Ended

Phase IV

5 trials
  • Care Arthritis Ltd. Commercial
    UPADACITINIB
    2023-510242-24-00 2 countries 2025 n=58
    Recruiting
  • Care Arthritis Ltd. Commercial
    UPADACITINIB
    2025-522118-21-00 6 countries n=130
    Pending
  • Charite Universitaetsmedizin Berlin KöR Academic
    NAPROXEN; TOFACITINIB
    2023-505050-18-00 4 countries 2023 n=104
    Ended
  • St. Elisabeth Gruppe GmbH Katholische Kliniken Rhein-Ruhr Academic
    INFLIXIMAB
    2024-513213-13-00 1 country 2025 n=100
    Recruiting
  • Universitaetsklinikum Heidelberg AöR Academic
    IXEKIZUMAB
    2023-508976-12-00 1 country 2024 n=10
    Ended

Phase I

1 trial
  • Grey Wolf Therapeutics Limited Commercial
    IMP not specified
    2025-521315-39-00 5 countries 2025 n=36
    Recruiting

Phase I (Other)

2 trials
  • UCB Biopharma Commercial
    BIMEKIZUMAB
    2024-518689-29-00 2 countries n=8
    Pending
  • UCB Biopharma Commercial
    IMP not specified
    2025-522782-30-00 6 countries 2026 n=293
    Recruiting

Other

3 trials
  • Sun Pharmaceutical Industries Limited Commercial
    IMP not specified
    2024-512770-10-00 1 country 2024 n=50
    Ended
  • Sun Pharmaceutical Industries Limited Commercial
    IMP not specified
    2024-512771-12-00 1 country 2024 n=32
    Ended
  • Sun Pharmaceutical Industries Limited Commercial
    IMP not specified
    2024-512773-27-00 1 country 2024 n=54
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Sun Pharmaceutical Industries Limited Commercial 3 Other 0
UCB Biopharma Commercial 3 Phase I (Other), Phase III 1
Care Arthritis Ltd. Commercial 2 Phase IV 1
St. Elisabeth Gruppe GmbH Katholische Kliniken Rhein-Ruhr Academic 2 Phase II, Phase IV 1
Grey Wolf Therapeutics Limited Commercial 1 Phase I 1
Spyre Therapeutics Inc. Commercial 1 Phase II 0
Alfasigma S.p.A. Commercial 1 Phase III 1
Assistance Publique Hopitaux De Paris Academic 1 Phase II 1
AbbVie Deutschland GmbH & Co. KG Academic 1 Phase III 0
Charite Universitaetsmedizin Berlin KöR Academic 1 Phase IV 0
Universitaetsklinikum Heidelberg AöR Academic 1 Phase IV 0
New trials by year
2020
2
2023
2
2024
5
2025
5
2026
1
← All indication landscapes